Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002277 · ClinicalTrials.gov registry record · Phase 3

A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal Infections

A Phase 3 study, sponsored by Pfizer.

Completed
Registry status
Phase 3
Development phase

NCT00002277: Completed Phase 3 study, sponsored by Pfizer.

NCT00002277 is a Phase 3 study that has completed, run by Pfizer. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002277, a Phase 3 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 3
Development phase

Study Summary

To compare the safety, tolerance and efficacy of fluconazole and amphotericin B as treatment for biopsy proven fungal infections in major organs, disseminated infection, suspected fungal infection and fungemia in adult neutropenic and non-neutropenic patients without AIDS, AIDS related complex (ARC), or extensive burns. HIV seropositive patients are allowed only if they also have a malignancy.

Interventions

  • DRUG Fluconazole
  • DRUG Amphotericin B

Trial Details

FieldValue
Phase Phase 3
Pfizer

1,845 total trials

What the finished NCT00002277 record still lists

NCT00002277 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 2 interventions - of which Fluconazole is the first listed.

NCT00002277 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00002277 about?

NCT00002277 is a clinical study titled "A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal Infections". To compare the safety, tolerance and efficacy of fluconazole and amphotericin B as treatment for biopsy proven fungal infections in major organs, disseminated infection, suspected fungal infection and fungemia in adult neutropenic and non-neutropenic patients without AIDS, AIDS related complex (ARC)...

What is the current status of trial NCT00002277?

This trial is currently completed. It is a Phase 3 study.

What interventions are being tested in trial NCT00002277?

The interventions under investigation include: Fluconazole (DRUG), Amphotericin B (DRUG).

Who is sponsoring clinical trial NCT00002277?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Source: ClinicalTrials.gov NCT00002277, the US trial registry maintained by the National Library of Medicine. NCT00002277 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.